Novel cancer immunotherapy is being assessed in nationwide SURVIVE trial in adults with glioblastoma, and in studies for other applications in children and adults. The designation awarded to MimiVax Inc. provides more extensive, accelerated access to FDA resources supporting development…
Roswell Park Cancer Innovation SurVaxM Granted FDA Fast Track Designation
This post was originally published on this site